WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will report financial results for the first quarter ended March 31, 2009 on Monday, May 11, 2009, before the U.S. financial markets open.
